Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized rituximab maintenance versus standard rituximab plus corticosteroids in pemphigus
2022-000060-22Phase 4Active
- Sponsor
- Rouen University Hospital
- Start
- Jul 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of rituximab and corticosteroids in pemphigus vulgaris (PV) and pemphigus foliaceus (PF) (2 arms), sponsored by Rouen University Hospital. Primary endpoint: Number of relapses/flares by patient-year. Started Jul 2024; status: active.
02
Drugs
rituximabcorticosteroids
03
Conditions
pemphigus vulgaris (PV)pemphigus foliaceus (PF)
Beyond the preview
Go deeper on 2022-000060-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000060-22.